SOLVONIS THERAPEUTICS PLC

• ◆

  Material uncertainty over going concern

  The Directors are satisfied that the going concern basis of preparation remains appropriate. However, they draw attention to the fact that the Company's ability to continue as a going concern is dependent on the successful completion of further equity fundraising within the assessment period. This represents a material uncertainty as disclosed in the auditors report and the financial statements do not include any adjustments that would result from the going concern basis of preparation being inappropriate. Ultimately after considering all of these factors the Directors are comfortable with the financial statements being prepared on a going concern basis.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. SOLVONIS THERAPEUTICS PLC 2025-01-10 → present
2. GRAFT POLYMER (UK) PLC 2021-07-01 → 2025-01-10
3. GRAFT POLYMER (UK) LIMITED 2017-05-18 → 2021-07-01

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Kreston Reeves Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Directors are satisfied that the going concern basis of preparation remains appropriate. However, they draw attention to the fact that the Company's ability to continue as a going concern is dependent on the successful completion of further equity fundraising within the assessment period. This represents a material uncertainty as disclosed in the auditors report and the financial statements do not include any adjustments that would result from the going concern basis of preparation being inappropriate. Ultimately after considering all of these factors the Directors are comfortable with the financial statements being prepared on a going concern basis.”

Group structure

1. SOLVONIS THERAPEUTICS PLC · parent
   1. Awakn Life Sciences Corp 100% · Canada · Holding Co
   2. Awakn Life Sciences Inc 100% · Canada · Holding Co
   3. Solvonis Therapeutics UK R&D Limited 100% · UK · Holding Co
   4. Solvonis Therapeutics US R&D Limited 100% · USA · Holding Co
   5. 1233705. Ltd 100% · Canada · Holding Co
   6. Solvonis Therapeutics Ireland Holdings Limited 100% · Ireland · Holding Co
   7. Solvonis Therapeutics Ireland R&D Ltd 100% · Ireland · Holding Co
   8. Awakn LS Partnerships Limited 100% · Ireland · Holding Co

Significant events

• “7 Jan 2026 - US Patent Allowance | PTSD Programme: USPTO granted a Notice of Allowance for Solvonis' SVN-SDN-14 PTSD for a series of compounds within its proprietary SVN-SDN-14 Post-Traumatic Stress Disorder ("PTSD") discovery programme”
• “28 Jan 2026 - SVN-015 Expanded into Depression: Solvonis announced the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data demonstrating antidepressant-like activity benchmarked against fluoxetine.”
• “10 Mar 2026 - SVN-114 Selected as PTSD Lead Candidate: Solvonis announced the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery programme targeting Post-Traumatic Stress Disorder ("PTSD").”
• “31 Mar 2026 - US Patent Granted: Solvonis announced that it had been granted a U.S. patent by the United States Patent and Trademark Office ("USPTO") covering a monoamine modulator compound series arising from its proprietary post-traumatic stress disorder ("PTSD") discovery programme.”
• “8 Apr 2026 - Second US Patent Granted: Solvonis announced that it had been granted a second U.S. patent by the United States Patent and Trademark Office ("USPTO") covering a further monoamine modulator compound series arising from its proprietary post-traumatic stress disorder ("PTSD") discovery programme.”
• “22 Apr 2026 - Appointment of Water Tower Research: Solvonis announced the appointment of Water Tower Research LLC to support the Company in three areas of increasing importance: deepening its understanding of the evolving U.S. market environment, refining its corporate profile in that market, and broadening intuitional investor reach.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

4

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.